FDA ODAC: STARGLO Glofitamab DLBCL Trial Inapplicable for US Populations
Andrew MorenoAggressive B-Cell Lymphoma | May 23, 2025

The FDA’s Oncologic Drugs Advisory Committee regards the STARGLO international clinical trial of glofitamab plus gemcitabine and oxaliplatin for DLBCL to be inapplicable to patient populations in the United States.

Advertisement
Advertisement

Advertisement
Editorial Board

Podcasts

Rahul Banerjee, MD, FACPAcute Myeloid Leukemia | May 23, 2025
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
Listen Now
Rahul Banerjee, MD, FACPMyeloma | May 5, 2025
Gurbakhash Kaur, MD joins the host of The HemOnc Pulse Live! for a comprehensive discussion about the RedirecT-1 trial.
Saad Z. Usmani, MD, MBA, FACPThe HemOnc Pulse | November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Sangeetha Venugopal, MDThe HemOnc Pulse | November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Naval Daver, MDThe HemOnc Pulse | October 22, 2024
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Mazyar Shadman, MD, MPHThe HemOnc Pulse | September 27, 2024
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | September 17, 2024
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Afaf Osman, MDThe HemOnc Pulse | August 9, 2024
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.

Video Insights

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia

Trending on MashupMD

Network Websites